Search

Objective: To determine whether the β-lactam allergy delabeling was safe and cost-saving in Primary Care (PC) patients., Design: We have conducted a retrospective chart review of PC patients with β-lactam allergy label evaluated in our Allergy Unit between 2017 and 2022. SITE: Allergy Department. Hospital Virgen del Rocio (Sevilla)., Participants: A total of 391 patients labeled for β-lactam allergy in PC were studied., Main Measurements: (a) Outcome evaluation of a β-lactam allergy delabeling procedure. (b) A ratio between the total e-prescribed antibiotic cost and the number of treatment days (the experimental daily antibiotic cost or EDAC) before and after delabeling was analyzed in delabeled and truly allergic patients., Results: The results of skin testing were positive in 9.2% of the reported cases (36 of 391 patients). The reactions to oral provocation challenge (OPC) occurred in 2.14% of the patients who underwent negative skin testing to offending β-lactam (in 15 of 699 OPC). A total of 307 patients (78.5%) were delabeled; 70 (17.9%) had a β-lactam selective response and 14 (3.59%) reacted to both penicillin and cephalosporin. The EDAC before and after the procedure in delabeled patients was significantly lower (0.88 € vs 0.62 €, p<10 -3 ), than that observed in truly allergic group (0.87 € vs. 0.76 €, p=not significant)., Conclusion: To delabel β-lactam allergy in Primary Care patients is safe in most patients, cost-saving in antibioticotherapy, and allows identify the main clinical β-lactam allergy phenotypes that benefit from this procedure., (Copyright © 2024 The Author(s). Publicado por Elsevier España S.L.U. All rights reserved.)

Objective: To review the etiology, diagnosis, prevention and treatment of latex allergy in the hospital setting, and to establish a list of potentially hazardous drugs., Method: A literature search was performed. A guide about latex-containing drugs (any component) was developed by contacting manufacturers., Results: The most relevant factor for latex sensitization is exposure extent. Regarding diagnosis the medical history and skin testing are crucial; regarding secondary prevention, identifying the various at-risk groups. Immunotherapy is currently considered a valid option for the management of this condition., Conclusions: The development of a guide listing latex-containing drugs is essential for the primary prevention of allergic reactions to this substance in hospital.